Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer

作者：David Tai, Thierry Conroy, Joycelyn Jie Xin Lee, C.E. Chee, Chunyi Hao, Indra Wijaya, SushilK Aggarwal, Makoto Ueno, Hei‐Cheul Jeung, Najihah Mohd Hashim, Bing Jia, Li‐Tzong Chen, Krittiya Korphaisarn, Suebpong Tanasanvimon, Wen‐Chi Chou, E Cargullo, Nur Fa’izah Ab Muin, Myung Ah Lee, Akihiro Ohba, Shailesh Bondarde, Cosmas Rinaldi Adithya Lesmana, Lei Wang, Elizabeth Smyth, Takayuki Yoshino, Glenn Kunnath Bonney, George Pentheroudakis, Jens Samol, Andrés Cervantes, Eileen Poon, Michel Ducreux · 发表于：ESMO Open · 年份：2025 · DOI：10.1016/j.esmoop.2025.105826 · 被引用次数：11 · 研究领域：Pancreatic and Hepatic Oncology Research、Cancer Genomics and Diagnostics、Gastric Cancer Management and Outcomes

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer, published in November 2023, were adapted in December 2024, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with pancreatic cancer. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with pancreatic cancer representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Singapore Society of Oncology (SSO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with pancreatic cancer across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in drug approvals and reimbursement strategies between the different countries.